Gerresheimer’s High-Wire Act: A Tech Deal, a Divestiture, and a Creditor Lifeline

Gerresheimer balances new packaging tech and Centor sale with accounting probe, debt restructuring, and 58% stock plunge.

Gerresheimer is trying to run two races at once. On one track, the pharmaceutical packaging group is showcasing new technology and pushing ahead with a major asset sale. On the other, it is scrambling to resolve an accounting crisis that has left its financial calendar in tatters and its stock among the most volatile in German mid-caps.

The Düsseldorf-based company announced a partnership with Milliken & Company just ahead of the weekend, centered on the LeneX™ UltraGuard® additive system. The technology promises to improve moisture barriers in HDPE packaging by up to 40 percent — a critical feature for humidity-sensitive drugs. Gerresheimer’s subsidiary Bormioli Pharma had already deployed the system for a global pharmaceutical client, and the group plans to showcase the collaboration at the Interpack trade fair in Düsseldorf from May 7 to 13.

That operational signal, however, is being overshadowed by a balance-sheet crisis that has already forced Gerresheimer out of the SDAX, effective April 10. Internal investigations into potential accounting violations for 2024 and 2025 have delayed the audited annual report, with a second auditing firm now scrutinizing revenue recognition and inventory valuation. The company now expects to publish the audited accounts in June 2026, followed by a half-year report on July 14.

The scale of the financial strain is underscored by the debt restructuring. Creditors holding Schuldschein loans worth €870 million agreed in mid-April to extend repayment deadlines until the end of September 2026, with 96 percent voting in favor. Key loan covenants related to leverage ratios have been suspended through the third quarter. The stock jumped roughly 20 percent in the week following that news, climbing to €22.76 — well above its 52-week low of €15.57, though still down nearly 58 percent year-to-date.

The most powerful lever for repairing the balance sheet remains the planned sale of Centor Inc., Gerresheimer’s US subsidiary specializing in packaging systems for prescription drugs. With a book value of €292 million, Centor is considered the group’s most profitable segment. Morgan Stanley is running the process, and a double-digit number of interested parties are reportedly in the running. Gerresheimer aims to close the deal before the end of 2026.

Meanwhile, the separation of the Moulded Glass business is progressing, though its actual sale has been pushed beyond 2026. The Chicago Heights plant will close by year-end, with production shifting to facilities in Italy and India.

The stock’s annualized 30-day volatility now stands at roughly 95 percent, making it one of the most turbulent names in Germany’s small-to-mid-cap space. The relative strength index sits near 30 — technically oversold, but fundamentally still clouded by uncertainty. The BaFin investigation continues, and the professional oversight body APAS has initiated disciplinary proceedings against KPMG, the auditor that had issued unqualified opinions on the now-questioned financial statements.

For the current fiscal year, Gerresheimer is guiding for revenue between €2.3 billion and €2.4 billion with an adjusted EBITDA margin of 18 to 19 percent — but that forecast is explicitly contingent on the investigations not forcing further corrections. The audited accounts in June remain the single most important milestone: without them, the bank financing, the earnings outlook, and the annual general meeting all remain in limbo.